Since December 2019, coronavirus disease 2019 (COVID‐19) swept around the world and resulted in 2 463 153 confirmed cases with 172 260 deaths by April 22, 2020. Several studies had reported that severe patients showed higher levels of [d]{.smallcaps}‐dimer, prothrombin time (PT), and activated partial thromboplastin time (APTT).[^1^](#ctm242-bib-0001){ref-type="ref"} Alex et al suggested the use of thromboprophylaxis in COVID‐19 patients, particularly those with evidence of activation of the coagulation system on admission.[^2^](#ctm242-bib-0002){ref-type="ref"} However, the effective predictor of the interval between the admission time and negative RT‐PCR detection (ATN) is unknown.

We conducted retrospective study between February 13, 2020 and March 13, 2020 in Cancer Center of Wuhan Union Hospital (Wuhan, China), which was designated hospital to centralized admission COVID‐19 patients since February 13, 2020, to reveal the potential role for coagulation parameters in COVID‐19 patients. The diagnosis was confirmed according to the diagnostic standards in the "Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019‐nCoV) Infection" by the National Health Commission of the People\'s Republic of China. Based on this, disease severity was divided into mild type (I, with mild clinical symptoms but without imaging features of COVID‐19 infection), common type (II, with clinical symptoms such as fever and/ or respiratory symptoms and with imaging features of COVID‐19 infection), and severe type (III, comply with any one of the followings: respiratory rate ≥ 30/min, Oxygen saturation ≤ 93%, PaO~2~/FiO~2 ~≤ 300 mm Hg, and/or focus of COVID‐19 infection progress rapidly(≥50%/24 h)), and critical type (IV, ICU patient). Clinical characteristics and lab test results, including coagulation tests data, and time to get the endpoint (negative RT‐PCR detection for twice, in minimum 24 h sampling interval) were obtained from electronic medical records using a standardized data collection form. All these data were checked and reviewed by independent and experienced doctors. Critical type patients were excluded from our current study based on our research purpose. Blood samples were collected within 24 h after admission to perform coagulation testing, including APTT, PT, [d]{.smallcaps}‐dimer, AT III, FDP, INR, FIB, and TT.

The baseline clinical characteristics of non‐critical patients with COVID‐19 were shown in Table [1](#ctm242-tbl-0001){ref-type="table"}, and the coagulation results showed that the level of D‐dimer (1.42 ± 2.27) and fibrinogen (FIB, 4.36 ± 1.27) were higher in COVID‐19 patients compared with regular people, which indicated that the COVID‐19 patients were suffered from coagulation dysfunction.

###### 

Univariate analysis of clinical characteristics of patients according to ATN (cutoff value = 26). Continuous variables are presented as mean ± SD

  Parameter                           All patients    Percentage (%)   Normative values   ATN \< 26       ATN ≥ 26        *P*
  ----------------------------------- --------------- ---------------- ------------------ --------------- --------------- --------
  No.                                 110                                                 52              58              
  Age, years                          62.3 ± 13.3                                         56.83 ± 14.38   67.22 ± 10.06   \<.001
  Sex                                                                                                                     .129
  Male                                51              46.4                                32(61.5%)       27(46.6%)       
  Female                              59              53.6                                20(38.5%)       31(53.4%)       
  With underlying health conditions                                                                                       
  Hypertension                        33              30.0                                                                
  Diabete                             15              13.6                                                                
  COPD                                3               2.7                                                                 
  Cancer                              4               3.6                                                                 
  APTT, s                             37.45 ± 4.61                     28‐43.5s           36.94 ± 4.20    38.50 ± 4.77    .070
  PT, s                               13.46 ± 0.96                     11‐16s             13.21 ± 0.84    13.69 ± 1.00    .007
  D‐dimer, mg/l FEU                   1.42 ± 2.27                      \<0.5 mg/L FEU     36.94 ± 4.20    38.50 ± 4.77    .070
  AT III, %                           84.57 ± 15.28                    80‐120%            13.21 ± 0.84    13.69 ± 1.00    .007
  FDP, ug/ml                          5.12 ± 9.38                      \<5ug/ml           36.94 ± 4.20    38.50 ± 4.77    .070
  INR                                 1.05 ± 0.10                      0.8‐1.31           13.21 ± 0.84    13.69 ± 1.00    .007
  FIB, g/l                            4.36 ± 1.27                      2.0--4.0 g/l       36.94 ± 4.20    38.50 ± 4.77    .070
  TT, s                               17.57 ± 1.28                     14--21 s           13.21 ± 0.84    13.69 ± 1.00    .007
  Disease severity                                                                                                        \<.001
  I                                   18              16.4                                18(34.6%)       0(0%)           
  II                                  62              56.4                                28(53.8%)       34(58.6%)       
  III                                 30              27.2                                6(11.5%)        24(41.4%)       
  ATN, days                           23.7 ± 5.4                                          19.15 ± 4.36    27.81 ± 1.89    \<.001

Continuous variables are presented as mean ± SD. (COPD: Chronic Obstructive Pulmonary Disease; PT: prothrombin time; APTT: activated partial thromboplastin time; AT III: antithrombin Ⅲ; FDP: Fibrinogen degradation product; INR: International standard ratio; FIB: fibrinogen; TT: thrombin time; ATN: admission time to negative. Continuous variables were presented as means and standard deviations (mean  ±  SD) and categorical variables were presented as counts and percentages. Patient characteristics were compared using Student\'s t test for continuous variables. Pearson\'s chi‐square test or Fisher exact tests were conducted for categorical variables.)
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Studies had shown that the disease severity and prognosis of COVID‐19 patients were significantly affected by multiple confounding factors, especially by age and coagulation function.[^3^](#ctm242-bib-0003){ref-type="ref"}, [^4^](#ctm242-bib-0004){ref-type="ref"}, [^5^](#ctm242-bib-0005){ref-type="ref"} Consistently, our result showed that the higher disease severity population had a higher proportion of patients with abnormal coagulation function, especially for AT III, [d]{.smallcaps}‐dimer, and FIB, which showed significant differences (*P* \< .05, Figure [1A](#ctm242-fig-0001){ref-type="fig"}).

![A, the proportion of patients with abnormal coagulation function test parameters in different disease severity groups. "\*" represents *P* \< .05. B, AUC of parameters to predict ATN for patients with COVID‐19. (AUC, area under curve; 95% CI, 95% confidence interval). C, ATN‐dependent ROC analysis for patients with COVID‐19](CTM2-10-e42-g001){#ctm242-fig-0001}

Ling et al, showed that the median time from the onset of symptoms to first negative RT‐PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0‐11.0) days.[^6^](#ctm242-bib-0006){ref-type="ref"} Inconsistently, median time for ATN was 23.7 ± 5.4 days (Table [1](#ctm242-tbl-0001){ref-type="table"}), which may contribute to the older age for COVID‐19 patients in our study (62.3 years vs 44 years). More importantly, we set the negative RT‐PCR detection for two times as the observed outcome, which could avoid false negatives with maximum degree. Zhang et al. had respectively reported the prognostic value of D‐dimer on admission in COVID‐19 patients,[^5^](#ctm242-bib-0005){ref-type="ref"} but predicted value of D‐dimer level on ATN was still unclear. In this study, the COVID‐19 patients were divided into two groups and univariate analyze were conducted according to the median cutoff value of ATN = 26, and the result demonstrated that the coagulation function, especially D‐dimer, together with diagnosed age and disease severity were associated with ATN (Table [1](#ctm242-tbl-0001){ref-type="table"}). The area under the ROC (receiver operator characteristic) curve (AUC) showed that age, disease severity level, and D‐dimer level had the better predictive effect to ATN in COVID‐19 patients, the AUC were 0.719, 0.744, and 0.723, respectively (Figure [1B](#ctm242-fig-0001){ref-type="fig"} and [C](#ctm242-fig-0001){ref-type="fig"}).

1. CONCLUSION {#ctm242-sec-0020}
=============

In conclusion, our study revealed the correlation between highly deviating of coagulation function and high disease severity, also poor prognosis. Importantly, the result proved the accurately predicted value of high D‐dimer levels to longer ATN in non‐critical COVID‐19 patients.

[^1]: These authors contributed equally to this study.
